DURGA-1

A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)

Near Add Your Location

Huntsman Cancer Institute
University of Utah
Salt Lake City, UT
  • Accepting patients
University of Alabama at Birmingham
O'Neal Comprehensive Cancer Center
Birmingham, AL
  • Accepting patients
Moores Cancer Center
University of California UC San Diego Health
La Jolla, CA
  • Accepting patients
Sylvester Comprehensive Cancer Center (Main)
University of Miami Health System
Miami, FL
  • Accepting patients
Moffitt Cancer Center
Magnolia Campus
Tampa, FL
  • Accepting patients
University of Colorado Cancer Center
Anschutz Cancer Pavilion
Aurora, CO
  • Accepting patients
UVA Cancer Center
University of Virginia Health System
Charlottesville, VA
  • Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.